Metabolism and urinary disposition of N,N‐dimethyltryptamine after oral and smoked administration: a comparative study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
N,N‐dimethyltryptamine (DMT) is a widely distributed plant alkaloid that displays partial agonist activity at the 5‐HT 2A receptor and induces intense psychedelic effects in humans when administered parenterally. However, self‐administration studies have reported a total lack of activity following oral intake. This is thought to be due to extensive degradation by monoamine oxidase (MAO). Despite increased use of DMT and DMT‐containing preparations, such as the plant tea ayahuasca, the biotransformation of DMT in humans when administered alone is relatively unknown. Here we used high performance liquid chromatography (HPLC)/electrospray ionization (ESI)/selected reaction monitoring (SRM)/tandem mass spectrometry (MS/MS) to characterize the metabolism and disposition of oral and smoked DMT. Twenty‐four‐hour urine samples were obtained from 6 DMT users before and after intake of 25 mg DMT doses on two separate sessions. In one session, DMT was taken orally and in another it was smoked. After oral ingestion, no psychotropic effects were experienced and no DMT was recovered in urine. MAO‐dependent indole‐3‐acetic acid (IAA) represented 97% of the recovered compounds, whereas DMT‐N‐oxide (DMT‐NO) accounted for only 3%. When the smoked route was used, the drug was fully psychoactive, unmetabolized DMT and DMT‐NO rose to 10% and 28%, respectively, and IAA levels dropped to 63%. An inverse correlation was found between the IAA/DMT‐NO ratio and subjective effects scores. These findings show that in the smoked route a shift from the highly efficient MAO‐dependent to the less efficient CYP‐dependent metabolism takes place. This shift leads to psychoactivity and is analogous to that observed in ayahuasca preparations combining DMT with MAO inhibitors. Copyright © 2014 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
Self-citationThe globalization of ayahuasca: harm reduction or benefit maximization?
Tupper, K. W. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2006.11.001 · Cited by 212
Barker, S. A., McIlhenny, E. H., & Strassman, R. (2012) · Drug Testing and Analysis · doi:10.1002/dta.422 · Cited by 142
Self-citationEffect of some indolealkylamines on man
TURNER, W. J. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340130141020 · Cited by 88
Cited by
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F., Bastos, M. D. L., Guedes de Pinho, P., & Carvalho, M. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
Self-citationSampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx036 · Cited by 200
Self-citationBarker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Self-citationMorales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175
Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., Alonso, J. F., Mañanas, M. À., Barker, S., Friedlander, P., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.012 · Cited by 173
Self-citationdos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
“When ingested alone, DMT is metabolized by peripheral MAO-A and does not produce psychoactive effects (Riba et al., 2003, 2015).”
Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020) · Pharmaceuticals · doi:10.3390/ph13110334 · Cited by 117
“[91], reaffirming the quantitative significance of this metabolite.”
Backgrounddos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
Vogt, S. B., Ley, L., Erne, L., Straumann, I., Becker, A. M., Klaiber, A., Holze, F., Vandersmissen, A., Mueller, L., Duthaler, U., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02477-4 · Cited by 89
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
Self-citationPsychological variables implied in the therapeutic effect of ayahuasca: A contextual approach
Franquesa, A., Sainz-Cort, A., Gandy, S., Soler, J., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.012 · Cited by 58
Self-citationBouso, J. C., Pedrero-Pérez, E. J., Gandy, S., & Alcázar-Córcoles, M. Á. (2016) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2545 · Cited by 48
Self-citationStudies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Dean, J. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00232 · Cited by 37
“Since 1% of the parenteral dose of orally administered DMT is recovered as DMT itself in the urine of volunteers due to its rapid break down by liver MAOs (Riba et al., 2015), it has been suggested that analysis of other DMT metabolites in mammalian bodily fluids is an approach that may prove fruitful (Barker et al.,…”
BackgroundInfluentialHalberstadt, A. L. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.01.005 · Cited by 35
Metadata
- Authors
- Riba, J., McIlhenny, E. H., Bouso, J. C., & Barker, S. A.
- Venue
- Drug Testing and Analysis
- Publisher
- Wiley
- Published
- 2014-07-28
- Volume
- 7
- Issue
- 5
- Pages
- 401-406
- ISSN
- 1942-7603 (ISSN-L)
- 1942-7611
- OpenAlex
- W1649318184
- Cited by
- 97
- References
- 9
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.